北方药学
北方藥學
북방약학
JOURNAL OF NORTH PHARMACY
2014年
11期
102-103
,共2页
刘庆倩%顾涛%陈玲%顾金花%张庆慧%朱丽娟%高玉兰
劉慶倩%顧濤%陳玲%顧金花%張慶慧%硃麗娟%高玉蘭
류경천%고도%진령%고금화%장경혜%주려연%고옥란
铜绿假单胞菌%亚胺培南%耐药性
銅綠假單胞菌%亞胺培南%耐藥性
동록가단포균%아알배남%내약성
Pseudomonas aeruginosa%Imipenem%Drug resistance
目的:探讨我院2012~2013年临床分离出的耐亚胺培南铜绿假单胞菌的抗生素药敏情况,为临床合理使用抗菌药物提供指导。方法:采用VITEK2-Compact微生物鉴定仪及药敏分析系统对我院临床各标本进行鉴定及药敏分析,头孢哌酮/舒巴坦采用K-B法。结果:2012~2013年分离到IRPA646株,对头孢菌素类耐药率为20.1%~100%,头孢他啶为43.3%,头孢吡肟为20.1%;对喹诺酮类抗生素耐药率为28.1%~30.4%;对氨基糖苷类耐药率为8.0%~12.9%;对β-内酰胺酶抑制剂类耐药率为24.5%~31.7%。结论:耐亚胺培南铜绿假单胞菌的耐药性严峻,临床应根据药敏结果选择用药,建议优先选用头孢他啶和头孢吡肟。
目的:探討我院2012~2013年臨床分離齣的耐亞胺培南銅綠假單胞菌的抗生素藥敏情況,為臨床閤理使用抗菌藥物提供指導。方法:採用VITEK2-Compact微生物鑒定儀及藥敏分析繫統對我院臨床各標本進行鑒定及藥敏分析,頭孢哌酮/舒巴坦採用K-B法。結果:2012~2013年分離到IRPA646株,對頭孢菌素類耐藥率為20.1%~100%,頭孢他啶為43.3%,頭孢吡肟為20.1%;對喹諾酮類抗生素耐藥率為28.1%~30.4%;對氨基糖苷類耐藥率為8.0%~12.9%;對β-內酰胺酶抑製劑類耐藥率為24.5%~31.7%。結論:耐亞胺培南銅綠假單胞菌的耐藥性嚴峻,臨床應根據藥敏結果選擇用藥,建議優先選用頭孢他啶和頭孢吡肟。
목적:탐토아원2012~2013년림상분리출적내아알배남동록가단포균적항생소약민정황,위림상합리사용항균약물제공지도。방법:채용VITEK2-Compact미생물감정의급약민분석계통대아원림상각표본진행감정급약민분석,두포고동/서파탄채용K-B법。결과:2012~2013년분리도IRPA646주,대두포균소류내약솔위20.1%~100%,두포타정위43.3%,두포필우위20.1%;대규낙동류항생소내약솔위28.1%~30.4%;대안기당감류내약솔위8.0%~12.9%;대β-내선알매억제제류내약솔위24.5%~31.7%。결론:내아알배남동록가단포균적내약성엄준,림상응근거약민결과선택용약,건의우선선용두포타정화두포필우。
Objective:To investigate the antibiotic drug sensitivity of imipenem resistant Pseudomonas aeruginosa (IRPA) in our hospital during 2012 to 2013, and provide the guidance for clinical rational use of antibiotics. Methods:All clinical specimens were collected, and then identified using VITEK2-Compact, analyzed drug sensitivity, Cefperazon-Sulbactam susceptibility testing was carried out using Kirby- Bauer method. Results:The 646 IRPA were isolated from 2012 to 2013, of which 20.1%~100% were resistant to cephalosporin antibiotics, 43.3% were resistant to ceftazidime, 20.1% were resistant to cefepime, 28.1%~30.4% were resistant to quinolone antibiotics, 8.0-12.9%were resistant to aminoglycoside, 24.5%~31.7% were resistant to β-lactamase inhibitor. Conclusion :The condition of antimicrobial resistance of IRPA was quite severe, antibiotics should be selected according to clinical drug susceptibility results and suggested that the priority to choose cefepime and ceftazidime.